Now the big question for patients and patients like yourself is that, if youre willing to do this right, to switch to a biosimilar, the question you should be asking, its not really from your healthcare professional, or your pharmacist or anybody else, but from your insurance company is that whether youre or not, going to get those savings passed on to you directly at the point of sale, instead of being hoarded by the PBMs and insurers
J Clin Oncol 37(Suppl 4
This is the recommended dilution for the 80mg Klow vial it produces clean, round numbers for every common dose
Haucke, A
[Abstract]2025 Nov 7;11(1):511
A method for isolating a peptide, the method including purification of a GLP-1 peptide from a mixture comprising said peptide and related impurities via an anion exchange chromatography process, the anion exchange chromatography process comprising the steps of:separating said GLP-1 peptide and said related impurities of said mixture by elution in a solution consisting essentially of an organic modifier, water, optionally a salt component, and optionally a buffer, with a linear or step gradient or isocratically in salt component and/or with a linear or step pH-gradient or at a constant pH-value, wherein the pH-gradient or pH-value should be in the range where said peptide has a negative local or overall net charge different from the local or overall negative net charge of said related impurities so as to remove said related impurities;and subsequently, if necessary, subjecting to analytical tests and/or further purification, and isolating said peptide in a conventional manner, wherein the ratio of organic modifier to water, on a weight percent basis, is from 1:99 to 99:1, such as 1:99 to 80:20, 20:80 to 80:20, 30:70 to 70:30, 35:50 to 50:35, or 40:50 to 50:40
